Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene
About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.
Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.
Cipla has struck a 'de-risked' deal to acquire the specialty firm Avenue Therapeutics, Inc, for up to $215m as it readies a niche play in the US pain management segment amid the opioid crisis.
GlaxoSmithKline has identified five core therapy areas including dermatology, gastrointestinals and the respiratory segment for a focused effort to accelerate growth on the competitive Indian market. Segments like central nervous system (CNS) and the government institutional business could potentially be defocused.